Astellas Provides Update on Fezolinetant New Drug Application in U.S. ...Middle East

TOKYO, Feb. 19, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the U.S. Food and Drug Administration (FDA) notified the company that it is extending the original priority review Prescription Drug User Fee Act...

Hence then, the article about astellas provides update on fezolinetant new drug application in u s was published today ( Monday 20/02/2023 - 02:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Provides Update on Fezolinetant New Drug Application in U.S. )

Also on site :

• ‘The Comeback’ Incited Public Confusion While Recreating 2023 Strikes Outside WB Lot: “Cars Were Honking”
• Gemini Space Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Gemini Space Station, Inc. - GEMI
• Noah Wyle tells hearing that 'The Pitt' shows TV and film production in the US can be revived